Novo Nordisk A/S (VIE:NNO2)

Market Cap	173.69B -31.9%
Revenue (ttm)	43.86B +8.1%
Net Income	16.32B +16.6%
EPS	3.67 +16.8%
Shares Out	n/a
PE Ratio	10.64
Forward PE	14.41
Dividend	1.57 (4.00%)
Ex-Dividend Date	Mar 27, 2026

Volume	9,887
Open	39.25
Previous Close	39.21
Day's Range	38.92 - 39.71
52-Week Range	30.01 - 71.63
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 6, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 67,900
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: NNO2

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK